CGM System Statistics in US 2026 | Users, Market & Key Facts

CGM System in America 2026

A Continuous Glucose Monitor (CGM) is a wearable medical device that automatically measures glucose levels in the body’s interstitial fluid — the fluid surrounding cells just beneath the skin — every few minutes, 24 hours a day, 7 days a week, without the need for repeated fingerstick blood draws. A small disposable sensor, typically replaced every 7 to 15 days depending on the brand, is inserted just under the skin and continuously relays glucose readings to a transmitter that syncs wirelessly — via Bluetooth — to a smartphone app, dedicated receiver, or smartwatch. The device not only displays current glucose levels in real time but also shows trend arrows indicating whether glucose is rising rapidly, rising slowly, stable, falling slowly, or falling rapidly — information that is clinically far more useful than a single point-in-time fingerstick reading. Users and their healthcare providers can also set customizable alerts for high glucose (hyperglycemia) or dangerously low glucose (hypoglycemia) events, providing a safety net that traditional blood glucose meters simply cannot offer. CGM systems represent the most significant advance in diabetes management technology since the introduction of home blood glucose meters in the early 1980s, and their integration with automated insulin delivery (AID) systems — so-called “closed-loop” or artificial pancreas systems — has transformed diabetes management from a reactive to a genuinely proactive discipline for millions of Americans.

In 2026, the CGM market in the United States sits at a remarkable convergence point: it is simultaneously a mature medical device category with established reimbursement pathways, a rapidly expanding consumer wellness product, and the foundation for the next generation of AI-driven personalized health management. The U.S. CGM market is valued at approximately $6.28–$7.43 billion in 2025–2026 — depending on the research firm’s scope — and is projected to grow at a CAGR of 16–18% through the early 2030s, driven by three powerful and converging forces. The first is the expanding diabetes epidemic: with 38.4 million Americans living with diabetes and another 96 million with prediabetes (CDC data), the addressable patient base for CGM is enormous and growing. The second is the Medicare and insurance coverage expansion: the 2023 CMS rule that extended CGM reimbursement to Type 2 basal-only insulin users instantly expanded the insured CGM population by an estimated 1.5 million beneficiaries. The third is the over-the-counter revolution: the March 2025 FDA clearance of the Dexcom Stelo — the first OTC CGM approved for non-prescription sale to individuals without diabetes — has opened an entirely new wellness market that existing prescription-only distribution could not reach. Together, these forces are transforming CGM from a specialized diabetes management tool into something approaching a mass-market personal health device — a trajectory that no other medical monitoring technology has followed so rapidly or so successfully.

Interesting Facts About CGM Systems in the US 2026 | Key Stats at a Glance

Source: Mordor Intelligence — US CGM Market Report 2026 (January 2026, mordorintelligence.com); Global Market Insights — US CGM Market (gminsights.com, September 2025); Grand View Research — CGM Devices Market (grandviewresearch.com); Precedence Research — CGM Device Market (October 2025); Future Market Insights — CGM Systems Market (May 2025); Knowledge Sourcing Intelligence — CGM Market (knowledge-sourcing.com); CDC — Adult Diabetes Prevalence Surveillance (cdc.gov); Grand View Research (April 2025 Dexcom G7 FDA clearance cited); Research Markets / BusinessWire (January 2025)

The key facts above capture an industry undergoing simultaneous maturation in its core market and explosive expansion at its edges. The ~98% market concentration among just three companies — Dexcom, Abbott, and Medtronic — reflects the massive clinical validation, regulatory investment, and payer relationship work required to build a successful CGM business, and creates significant barriers to entry for new competitors. At the same time, the first-ever OTC CGM approval in March 2025 opened a mass-market door that no established medical device company had previously been able to unlock — and the estimate that the OTC CGM market alone will reach $2.14 billion in the US by 2034 signals that the consumer wellness angle is not a niche but a structural expansion of the total addressable market. The RFK Jr.-led MAHA initiative promoting CGM adoption in June 2025 — whatever its political context — is functionally a federal tailwind for the entire CGM market, potentially accelerating both awareness and adoption among the vast pool of 96 million prediabetic Americans who are newly eligible for wellness-oriented glucose monitoring.

CGM Systems 2026 – US Market Size & Revenue Statistics

Source: Mordor Intelligence — US CGM Market and Global CGM Market Reports (January 2026); Global Market Insights — US CGM Market (September 2025); Grand View Research — CGM Devices Market 2033; Precedence Research — CGM Device Market (October 2025); Future Market Insights — CGM Systems Market (May 2025); Mordor Intelligence — North America CGM Market (February 2026)

The CGM market revenue trajectory from $3.4 billion in 2021 to a projected $22 billion by 2034 in the United States alone represents one of the most sustained high-growth curves in the medical device industry — and unlike many healthcare growth stories, this trajectory is supported by genuine and growing clinical evidence rather than speculative demand. The growth from $5.7–$6.28 billion in 2025 to $6.16–$7.43 billion in 2026 — an 18% annual increase for the US market — reflects the immediate financial impact of the combined forces of Medicare expansion, OTC approvals, and the steady erosion of sensor prices below the psychologically and practically important $100 per 14-day wear period threshold. That price point is significant: it brings the per-day cost of CGM monitoring to approximately $7 per day — below the cost of many daily medications and well within the range where insurance reimbursement makes the consumer’s out-of-pocket burden manageable.

The sensor market’s 87% share of total CGM revenue is the defining structural feature of the business model: CGM is a razor-and-blades market, where the initial hardware cost of the transmitter is largely a gateway to the recurring, high-margin stream of disposable sensor revenue. Every new CGM user generates 26 sensor purchases per year (at 14-day wear), creating predictable, long-duration annuity revenue that rewards companies that capture and retain patients early in their diabetes journey.

CGM Systems 2026 – User Statistics & Adoption Rates

Source: Mordor Intelligence — US CGM Market 2026 (citing CDC surveillance data); PMC/NIH — “Rates and Correlates of Uptake of CGM Among Adults with Type 2 Diabetes” (pmc.ncbi.nlm.nih.gov, 10228889); American Diabetes Association — “Patterns and Trends in CGM Utilization Among Type 1 Diabetes” (Clinical Diabetes, 2024); PMC/NIH — “Association of CGM Use and HbA1c Levels” (9331081); Future Market Insights — CGM Systems Market (May 2025, citing Dexcom CEO Kevin Sayer PBM coverage statement); Grand View Research; Global Market Insights (gminsights.com)

The adoption statistics reveal a CGM market that has fully penetrated its earliest and most motivated adopter segment — Type 1 diabetes patients — and is now in the middle of the more challenging and potentially far larger Type 2 expansion. The journey from 20% CGM utilization among commercially insured Type 1 patients in 2010–2013 to approximately 50% in 2016–2019 was already described as a “2.5-fold increase in less than 10 years” by the American Diabetes Association — and current estimates suggest utilization in well-insured Type 1 populations has now risen to 60–80%, with the remaining gap largely attributable to patients with public insurance or lower incomes. The Type 2 story is different: only 13% of Type 2 patients in a large academic center study had used CGM as of 2021, and the majority of those were on intensive insulin regimens — meaning CGM for the non-insulin-using Type 2 majority was essentially nonexistent before the Medicare expansion and the OTC approvals of 2023–2025.

The racial disparities in CGM adoption deserve particular attention: Black patients represent only 1.73% of CGM users despite accounting for 5.43% of the Type 1 diabetes population — a threefold underrepresentation that reflects the intersection of insurance coverage gaps, healthcare access disparities, and the documented pattern that CGM users are disproportionately younger, privately insured, and higher-income. These disparities exist despite the clinical evidence that CGM significantly improves glycemic control: CGM users had a mean HbA1c of 7.90% versus 8.86% for non-users — a gap that translates directly into reduced risk of the devastating long-term complications of diabetes including kidney disease, neuropathy, and cardiovascular events.

CGM Systems 2026 – Key Devices — Dexcom, Abbott & Medtronic

Source: Grand View Research (April 2025 — Dexcom G7 15-Day FDA clearance); Global Market Insights (gminsights.com); Mordor Intelligence — US CGM Market 2026; Knowledge Sourcing Intelligence — CGM Market (citing Abbott/Medtronic partnership August 2024; Senseonics September 2024; Senseonics distribution Jan. 2026; Signos August 2025); Future Market Insights (May 2025, citing Dexcom CEO Kevin Sayer on PBM coverage); Precedence Research (citing Roche $550M investment May 2025)

The CGM device landscape in 2026 is defined by two parallel tracks: the continued evolution of prescription medical devices for active diabetes management and the emerging consumer wellness OTC segment. On the prescription side, Dexcom and Abbott together control approximately 88% of the US market, and the April 2025 clearance of the Dexcom G7 15-Day version — extending the top-selling CGM from 10 to 15 days per sensor — represents exactly the kind of incremental but clinically and economically meaningful improvement that has sustained these companies’ leadership positions. Fewer sensor changes per month means fewer associated costs, less patient burden, and lower per-month sensor expenditure, making CGM more sustainable for long-term daily use across the patient’s lifetime.

The Senseonics Eversense 365 — a fully implantable CGM lasting a full year before requiring a simple in-office replacement — represents the most radical alternative to the dominant disposable patch-sensor model. By eliminating the weekly or biweekly sensor change ritual that many patients find burdensome, the Eversense 365 addresses one of the primary adherence barriers for CGM use, particularly in older patients and those with limited manual dexterity. The new distribution arrangement with Ascensia Diabetes Care beginning January 1, 2026 signals a renewed commercial push for the platform. Meanwhile, the Signos FDA clearance in August 2025 — specifically approved for weight management rather than diabetes management — is potentially the most consequential regulatory decision for expanding CGM’s total addressable market, directly targeting the obesity and metabolic health consumer segment that represents hundreds of millions of potential users globally.

CGM Systems 2026 – Reimbursement, Policy & Access Statistics

Source: Mordor Intelligence — US CGM Market 2026 (January 2026, CMS 2023 rule and Medicare expansion); Future Market Insights (May 2025, citing Dexcom PBM coverage statement); Global Market Insights (March 2025, Dexcom Stelo OTC FDA clearance); Grand View Research (citing RFK Jr. MAHA initiative June 2025); Precedence Research (Roche investment May 2025); Knowledge Sourcing Intelligence — CGM Market (ADA standards of care and telehealth integration)

The reimbursement and policy landscape in 2026 has been more favorable for CGM adoption than at any point in the device’s history — and two specific policy events have created step-change expansions in the addressable market. The 2023 CMS rule extending Medicare coverage to basal-only insulin users was the single most impactful reimbursement change in CGM history: at a stroke, it made approximately 1.5 million Medicare beneficiaries eligible for covered CGM who had previously been excluded. This cohort — elderly Type 2 patients on once-daily long-acting insulin — is exactly the group at highest risk of undetected nocturnal hypoglycemia, which makes the clinical case for CGM coverage in this population as strong as for any other.

The OTC CGM revolution enabled by the March 2025 Dexcom Stelo approval and the June 2024 Abbott Lingo and Libre Rio clearances represents a structural transformation of how CGM reaches consumers: for the first time, anyone can walk into a pharmacy, purchase a CGM, and start monitoring their glucose without seeing a physician. This has profound implications for the 96 million Americans with prediabetes — a population that currently has no clinical guideline recommending CGM but who could potentially use real-time glucose data to understand how food, exercise, and stress affect their metabolic health, potentially delaying or preventing progression to diabetes. The OTC market’s $2.14 billion US projection by 2034 reflects analysts’ confidence that this new consumer channel will become substantial — though it will require ongoing consumer education to ensure appropriate interpretation of CGM data outside the clinical context.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE